The global renal biomarkers market size was valued at USD 1165.14 Million in 2023. The global market size is expected to reach USD 1778.1 Million by 2029 from USD 1250.2 Mn in 2024, growing at a CAGR of 7.3% during the forecast period.
A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes pathogenic process responses to a therapeutic intervention. Renal biomarker consists of serum creatinine (SCR), blood urea nitrogen (BUN), urinary albumin/protein, and volume excretion.
Acute kidney injury (AKI) and chronic kidney disease (CKD) substantially increase morbidity and mortality. Some researchers are going into the laboratories to develop a procedure to diagnose acute kidney injury and chronic kidney diseases with surrogate marker GFR, such as serum creatinine (SCr). The growing demand for innovative techniques in the medical sector is driving the need of the market. The government organization is working towards the development in the field of renal biomarkers as there is a tremendous demand for the non-invasive biomarker process. Increasing scale research centers are also propelling the growth rate of the market.
Increasing R & D activities and rising diagnostic applications of biomarkers are further anticipated to further flourish the renal biomarkers market. Contract Research Organizations (CROs) are increasing in huge numbers, which is estimated to favor the market's growth rate. The development rate of chronic kidney diseases among children increases, which is anticipated to impel the market demand. In 2018, according to the European Renal Association- European Dialysis and Transplant Association data, more than 850 million people were diagnosed with kidney disease. The vast number of patients affected with a different form of kidney disease is rising, which is leading to the improvement of new renal biomarkers that are expected to bolster the market growth.
The current biomarkers are not specific and cannot work at a particular target as they cannot detect some of the diseases. There is no adequate or proper way to detect acute and chronic kidney diseases, which is estimated to hinder the renal biomarkers market growth. Furthermore, an inappropriate way to identify acute and chronic kidney diseases is one major factor in limiting the market growth. Inadequate reimbursement policies impede market demand. Usage of irregular and imperfect standard quality is predicted to hinder the renal biomarkers market growth in Europe. Hurdles associated with regulatory bodies are likely to restrict the market. The vast amount required for drug discovery, development, and establishment is obstructing market growth.
The novel coronavirus (COVID-19) is a transmitted disease that is caused by the SARS-CoV-2 reagent. The coronavirus has affected all parts of the body like cardiovascular, gastrointestinal, and other organ diseases. The patients with COVID-19 symptoms have kidney diseases, and their involvement is widespread. The sudden outburst of COVID-19 has had considerable effects on the occurrence and management of kidney diseases. The high incidences of diabetes and blood pressure are the primary cause of kidney-related diseases. COVID-19-associated acute kidney injuries are concerned with death rates and serve as independent risk factors for all-cause in-hospital death in patients with COVID-19. The advancements of regional increase in COVID-19 cases limit hospital resources. Because of the quick advancements in genomic technologies, genetics analysis has become essential in clinical practice and research. Renal biomarkers are integrated with genetic-level technological developments to detect, diagnose, and treat kidney diseases—the occurrences of kidney injuries or damages and their association with the urinary biomarkers in hospitalized COVID-19 patients.
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2023 to 2029 |
|
Base Year |
2023 |
|
Forecast Period |
2024 to 2029 |
|
Segments Covered |
By Diagnostic Technique, Type, End-User, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
|
Key Market Players |
Abbott Diagnostics, F. Hoffmann-La Roche AG, Beckman Coulter Inc., Astute Medical Inc., Siemens Healthcare Diagnostics Inc., Thermo Fisher Scientific Inc., Alere Inc., bioMérieux SA, and Randox Laboratories Ltd. |
The enzyme-linked immunosorbent assay segment led the renal biomarkers market in 2023, accounting for 44.3% of the global market share, and the domination of the segment is expected to continue during the forecast period owing to the rising demand to promote quality healthcare services.
The functional biomarker segment is expected to hold the largest share of the market during the period and is observed to have a CAGR value of 6.94% or renal biomarkers. Increasing chronic kidney diseases and creating awareness of serum creatinine biomarkers by private and public sectors elevate the market demand.
The diagnostic labs are considered to have the largest market share. Diagnostic labs account for 34.9% in terms of value over the forecast period. The Outpatient clinic's segment is expected to register a CAGR value of a 7.2% share of renal biomarkers growth. The growing economy in both developed and developing countries is favoring segmental expansion.
The North American region occupied most of the share in the global renal biomarkers market in 2023. The area has contributed 32% of the U.S. share owing to the escalating expenditure on healthcare, strong economic growth, and receiving novel diagnostic methods. The U.S. holds the highest shares of the market and is continuing the same growth rate during the period.
The European market is expected to showcase promising growth for the growth of renal biomarkers during the analysis period. The increase in this region is expected to have a share of 21.1% of the market. The factors responsible for the growth are adopting the latest technology in the healthcare sector and the high expenditure capacity of the population. The UK is accounted to hold the top position with the largest share in the market. Quick launches and inventions of products to improve healthcare services and infrastructure are escalating the market demand. Notable growth in the elder people population leading to the increase of disease ailments expands the market portfolio. Germany, France, Italy, Spain, and the rest of Europe are projected to have considerable growth in the renal biomarkers market. Rapid advancements in genetics, which lead to the enhancement of upgraded renal biomarkers in treating patients with kidney disorders, are thriving in the market growth.
The Asia-Pacific market is expected to have the fastest growth rate over the analysis period. Soaring occurrences of renal diseases, growing older people population, and inadequate reimbursement policies are likely to hamper the growth of the renal biomarkers market. Countries like India and China are considered to provide a high range of opportunities for the renal biomarkers market.
The Latin American market is expected to have steady growth over the period owing to the adoption of advanced technology. Growing occurrences of diseases like high blood pressure and diabetes are some factors propelling the market's demand. Brazil is deemed to have enormous market opportunities with increasing support from private and public healthcare expenditure.
The Middle East & Africa region has a steady growth rate. The growing geriatric population, increasing diabetic population, rising awareness of acute and chronic kidney diseases, and increasing diagnostics and therapeutic procedures are significant factors for growth in this region. In this region, the South African market is soaring due to strong growth in healthcare and reimbursement programs from the government in developing countries.
Noteworthy companies playing a leading role in the global renal biomarkers market profiled in the report are Abbott Diagnostics, F. Hoffmann-La Roche AG, Beckman Coulter Inc., Astute Medical Inc., Siemens Healthcare Diagnostics Inc., Thermo Fisher Scientific Inc., Alere Inc., bioMérieux SA, and Randox Laboratories Ltd.
By Diagnostic Technique
By Type
By End User
By Region
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region